Phil Tennant, chief commercial officer of Precigen Inc., disposed of 79,166 common shares on August 25, 2026, generating proceeds of $593,745 at a price of $7.50 per share. The sale was executed under a pre-established Rule 10b5-1 trading plan, a standard mechanism designed to mitigate insider trading risks.
The transaction followed two related events on August 23 and 25, 2026. Tennant received 5,208 shares as part of a restricted stock unit (RSU) settlement, with 2,585 shares withheld to cover $18,612 in income tax obligations at $7.20 per share. On August 25, he also exercised options to purchase 79,166 shares at $1.61 each, a move that contributed an additional $127,457 in value to his holdings. The RSUs vested incrementally from a grant dated June 26, 2025, while the options began vesting on July 22, 2025, with a 25% initial tranche followed by equal monthly installments over three years.
Precigen’s stock has appreciated 83% over the past year, trading near its 52-week high of $7.55. Analytical data provider InvestingPro estimates a fair value of $7.33 for the shares. The company reported second-quarter 2026 earnings per share of $0.05, exceeding expectations of a $0.01 loss, alongside revenue of $54.98 million against a forecast of $27.83 million and net income of $20.1 million.
